Conference Co-Hosts

University Of Michigan

2017 saw technology innovations, new therapies and diagnostics, value-based healthcare, and clinical protocol advancements as huge drivers, moving the needle from a one-size-fits-all model to personalized healthcare.

Some of the biggest impacts include:

  • Clearing CAR-T therapies for advanced lymphoma and Spark Therapeutics’ gene therapy for blindness by the FDA after decades of research
  • Foundation Medicine achieving FDA approval for its NGS-based FoundationOne genomic profiling cancer test, concurrent with the Centers for Medicare and Medicaid Services (CMS) issuing a preliminary national coverage determination for the test and others like it
  • Editing genes for gene therapy or controlling its expression via one of the most exciting innovations, the CRISPR-Cas9 technology, currently revolutionizing the field
  • Being able to understand and sequence complex DNA regions applying long-read technologies
  • Recognizing the importance of the microbiome and its impact on human health and translating learnings into therapies and diagnostics
  • New technologies such as liquid biopsy, cfDNA detection, and artificial intelligence/machine learning in genomics and drug discovery

The advancements were paradigm-shifting, especially when the different sectors of technology, research, healthcare, pharmaceutical, medical & equipment providers, and regulatory sectors converged.

On the technology side, big data analysis, artificial intelligence, and machine/deep learning made its mark with numerous applications in drug discovery, clinical diagnostics, and clinical trial optimization. With this rise, many companies are pushing the limits of disease understanding, diagnosis and therapy. Considering the need to automate and scale disease diagnosis, it has even been provocatively suggested that AI – once fully optimized and implemented – will one day replace human oncologists. While we see a huge uptick in AI/machine learning companies working feverishly on new solutions in this sector across the globe, we also hear doubt across the industry that AI is ready. Is it hype or reality? 2018 promises to provide insight and help clarify where we stand.

The CRISPR-Cas9 technology clearly dominated the research and applications sector promising the first set of its applications to enter clinical trials in 2018.

On the regulatory side, the FDA made strides with streamlining the development and review pathway for consumer tests that evaluate genetic health risks, approving Foundation Medicine’s FoundationOne CDx, Thermo Fisher Oncomine Dx Target Test, and Agilent’s GenetiSure Dx tests, while at the same time the FDA consumer advisory raised safety concerns related to the “Self-Administration” of illegal gene therapy products.

Medical and equipment providers continued with their delivery of powerful solutions that will impact the field of precision medicine, including Illumina’s NovaSeq, Oxford Nanopore’s GridION X5, or Mission Bio’s new Single-Cell DNA analysis platform Tapestri, to name a few.

The genetic testing sector is seeing a steady march forward with more companies providing a wider test spectrum. Color Genomics appears to be on a mission to democratize access to genetic testing via affordable and low cost cancer risk tests. The release of the Annual Report by UK Chief Medical Officer Dame Sally Davis provides evidence that genomics can improve health and prevent ill health. While this year saw a rise in testing coverages, some insurers worry about adverse selection and discrimination as the industry has not quite yet caught up with all the reimbursement demands and regulations that need to be put in place.

And then of course there is immunotherapy with its numerous successes including the newly developed CAR-T cell therapy, accompanied with Kyrmriah (Novartis) and Yescarta (Kite Pharma, now Gilead) approval, and Keytruda (Merck) becoming the first cancer treatment (anti-PD-1 immunotherapy) for (any) solid tumors based on a specific genomic profile. While the successes were celebrated, they also highlighted the new challenges of these drugs, including higher drug development process cost, and justification of the high overall therapy cost. Current Kyrmriah cost is $475K per treatment. The latter is a discussion point that the healthcare industry will surely need to address with all its stakeholders in mind as pressure from payors, advocacy groups, and providers are rising.

Astounding acquisitions (some of which went global) and massive financial investments occurred in 2017. The 1 billion dollar-valued company, GRAIL went global with the Cirina merger focusing on early cancer detection. Oxford Gene Technology was acquired by the Japanese in vitro diagnostics company Sysmex Corporation. At the same time, Invitae went on a shopping spree and acquired Ommodom’s CancerGene ConnectOn, Good Start Genetics, and CombiMatrix, focusing on enhancing their testing repertoire. Konica Minolta acquired Ambry Genetics in a $1 billion deal, and Gilead Sciences acquired Kite Pharma for $11.9 billion, again just to name a few examples. On the investment side, companies playing in artificial intelligence/machine learning (with Tempus, Sophia Genetics), digital health, and clinical genomics (Color Genomics, Counsyl, Edico Genome, Prenetics, WuXi NextCODE) seemed to be the big winners.

Last but not least, 2017 was also the year of more initiatives and large scale population studies including the new Big Data, Precision Medicine Network formed by five University of California precision medicine research centers, the recently launched Chinese Precision Medicine Initiative, the France Genome Medicine Plan, and the Precision Health at the University of Michigan Initiative, which – among other things – is focusing on opioid prescribing in the pre-surgical setting. For most studies, the aim is to better understand the link between genetics/specific genes and how they affect disease, while at the same time trying to integrate genomics for precision healthcare.

Given the paradigm shift, what better way is there than to ring in the New Year with the conference that highlights the latest significant developments changing the practice of medicine to personalized healthcare?

Be among the first to hear where the field is moving, what the next phase in this area of healthcare will look like, and how it will impact you and your business. PMWC 2018 has finalized a great lineup of speakers and representatives from 100,000 Genomics England, 23andMe, Agilent, Ambry Genetics, Foundation Medicine, GRAIL, Illumina, Invitae, Natera, Mission Bio, Oxford Nanopore, Thermo Fisher Scientific, and many more. Come join us for this information-rich gathering of the minds: it’s not too late!

Email [email protected] to inquire about being invited to the reception honoring Emmanuelle Charpentier (Max Plank Institute), Sir John Bell (Oxford University), Ronald Levy (Stanford), and Alan Ashworth (UCSF).

 

Happy New Year and Best Wishes for 2018 from the PMWC team!
650-961-8877
Don’t miss out. Join this timely conference now!
REGISTER

Interview with Dan Rhodes from Strata Oncology

Q: What need is Strata Oncology addressing?

Despite substantial advances in precision oncology, the majority of advanced cancer patients still do not benefit from comprehensive tumor molecular profiling or precision therapy trials.

Read More

Interview with Lisa McLaughlin from Workit Health

Q: What need is Workit Health addressing?

Drug overdoses killed more Americans last year than were lost during the entire Vietnam War (69,000).

Read More

Interview with Olivier Elemento from Weill Cornell Medicine

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

I direct the Englander Institute for Precision Medicine, an Institute that focuses on using genomics and informatics to make medicine more individualized.

Read More

Interview with Dr. Dunnenberger from NorthShore University HealthSystem

Q: What patient population is NorthShore University HealthSystem serving and which services are you specializing in?

NorthShore is a four hospital community health system with over 100 outpatient medical offices.

Read More

How Artificial Intelligence (AI) Will Potentiate Individualized Medicine

We had the chance to sit down with Dr. Topol to hear his thoughts on big data, digital health, sensors, and artificial intelligence, some of the newest precision medicine technologies.

Read More

Interview with Jennifer Kloke from Ayasdi

Q: What need is Ayasdi addressing?

Ayasdi is pioneering the application of AI to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Q&A with Eric Topol, Executive Vice President, Scripps Research Institute

Dr. Eric Topol, voted by Modern Healthcare as the most influential physician executive in the United States, shared his thoughts on why people should own and control their own data.

Read More

CMS to Approve Coverage of NGS-based Cancer Testing | Big Pharma’s Response & The effect on PM

Why this is a Big Deal? As we know, private insurers follow suit once Medicare makes a decision such as this. This portends well for genetic testing to become routine standard of care for patients with advanced cancers.

Read More

Q&A with Mickey Kertesz, Chief Executive Officer, Karius

Q: Tell us a little bit about Karius – what problem(s)/need(s) are you trying to address and what technology is behind it to achieve this?

Read More

Join PMWC 2018 Michigan This June to Learn More about How the Modulation of the Epigenome Increases the Risk for Type 2 Diabetes

Dr. Michael Boehnke (University of Michigan) – who pioneered large-scale studies identifying genetic risk in diabetes and bipolar disorder – shared with us some recent insights about recent advances in exome and genome sequencing and their applications to better understand disease biology and etiology of psychiatric disorders

Read More

AI and Machine Learning in Healthcare – Not Just Hype Anymore

AI and machine learning has gotten a lot of attention over the last year, as it appears to be poised to become one of the biggest game changer in many industries, including the healthcare sector.

Read More

Q&A with Eric Lefkofsky, CEO of Tempus and Co-founder of Groupon

“Treating a cancer patient without the benefit of modern software is the same as driving at night without headlights”

Read More

PMWC Michigan – Big Data in Action: Data-Driven Insights in the Clinic

We are excited to launch the first Precision Medicine World Conference (PMWC) at the University of Michigan June 6-7, 2018.

Read More

Q&A with Susan A. Murphy, Harvard University

Q: Your lab develops experimental trial designs and data analysis methods for increasing the usefulness of mobile health interventions. Can you please give examples how these trials are being used in the areas of substance abuse, physical activity, or helping people quit smoking?

Read More

Q&A with Dr. Dara Richardson-Heron, Chief Engagement Officer, All of Us

Q: Your reputation for passion about engaging and empowering people precedes you. Can you please describe your role at the All of Us Research Program?

Read More
University of Michigan

The 14th Precision Medicine World Conference (PMWC) will take place at the University of Michigan on June 6-7, 2018. This conference coincides with University of Michigan’s launch of a new Precision Health research initiative that integrates U of M’s strengths in Medicine, Engineering, Pharmacy, and Public Health. (hyperlink) This initiative combines biomedical expertise, big data, and the social sciences enabling a comprehensive approach to providing patients with tailored health solutions.

To support the University of Michigan’s goal to bring together leading researchers from across the university and the country to springboard this new and exciting research initiative, PMWC and U-M have agreed that the campus is an optimal location for the next conference. This forum will showcase practical content that helps close the knowledge gap among different sectors, thereby catalyzing cross-functional fertilization and collaboration to benefit both University of Michigan and PMWC attendees.

The program will feature innovative technologies, and analyze the success of already thriving initiatives and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advances in precision medicine and cutting-edge strategies and solutions that are fundamentally changing how patients are treated. This is reflected in the Program Theme: “Big Data in Action: Data-driven Insights in the Clinic”.

Agenda highlights:

    • More than 35 sessions with 100+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Two tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Changing Pharmacogenomics
    • Community Setting Challenges
    • Patient Issues and Challenges
    • Legal and Ethical Issues
    • Integrating genomic data into EMRs
    • Emerging Technologies
    • Personalized Health Care Delivery
    • Personalized Modeling of Precision Health
    • NIH’s All of Us Study
    • Big Data in Action
    • Opioid Precision Health
    • Neurosciences
    • Big Data in the Clinic
    • Wellness and Aging
    • Epigenetics and Aging
    • Precision Cancer Therapy
    • Data Sharing in Translational Medicine
    • Economic and Socio-political Issues

The 14th Precision Medicine World Conference (PMWC) will take place at the University of Michigan on June 6-7, 2018. This conference coincides with University of Michigan’s launch of a new Precision Health research initiative that integrates U of M’s strengths in Medicine, Engineering, Pharmacy, and Public Health. (hyperlink) This initiative combines biomedical expertise, big data, and the social sciences enabling a comprehensive approach to providing patients with tailored health solutions.

To support the University of Michigan’s goal to bring together leading researchers from across the university and the country to springboard this new and exciting research initiative, PMWC and U-M have agreed that the campus is an optimal location for the next conference. This forum will showcase practical content that helps close the knowledge gap among different sectors, thereby catalyzing cross-functional fertilization and collaboration to benefit both University of Michigan and PMWC attendees.

The program will feature innovative technologies, and analyze the success of already thriving initiatives and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advances in precision medicine and cutting-edge strategies and solutions that are fundamentally changing how patients are treated. This is reflected in the Program Theme: “Big Data in Action: Data-driven Insights in the Clinic”.

Agenda highlights:

    • More than 35 sessions with 100+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Two tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
        • Changing Pharmacogenomics
        • Community Setting Challenges
        • Patient Issues and Challenges
        • Legal and Ethical Issues
        • Integrating genomic data into EMRs
        • Emerging Technologies
        • Personalized Health Care Delivery
        • Personalized Modeling of Precision Health
        • NIH’s All of Us Study
        • Big Data in Action
        • Opioid Precision Health
        • Neurosciences
        • Big Data in the Clinic
        • Wellness and Aging
        • Epigenetics and Aging
        • Precision Cancer Therapy
        • Data Sharing in Translational Medicine
        • Economic and Socio-political Issues

 

Confirmed thought leaders include:

Lee Hood

Lee Hood

Chief Science Officer, Providence Health

Eric Topol

Eric Topol

Chief Academic Officer, Scripps Health

Francis Collins

Francis Collins

Director of the National Institutes of Health (NIH)

Vicki L. Ellingrod

Vicki L. Ellingrod

Ass. Dir., Michigan Inst. for Clinical & Health Research

Goncalo Abecasis

Goncalo Abecasis

Chair, Department of Biostatistics, UM

Jeffrey Leiden

Jeffrey Leiden

Chairman, President and CEO, Vertex

Matthias Kretzler

Matthias Kretzler

Professor, Nephrology & Internal Medicine, UM

Arul Chinnaiyan

Arul Chinnaiyan

Professor of Pathology, Medical Institute, UM

David Ginsburg

David Ginsburg

Prof., Human Genetics; Investigator, UM

Steve Nelson

Steve Nelson

Chief Executive Officer, UnitedHealthcare

Gil Omenn

Gil Omenn

Dir., Comput. Med. & Bioinformatics Center, UM

Eric Lefkofsky

Eric Lefkofsky

Founder and CEO, Tempus

Steven Leeder

Steven Leeder

Dir., Clin. Pharmacology Children’s Mercy Hospital,(CMH)

Ariella Shikanov

Ariella Shikanov

Assistant Professor, Biomedical Engineering, UM

Lawrence Corey

Lawrence Corey

Presi. & Dir. Emeritus, Fred Hutch Cancer Research Cent.

Amir Dan Rubin

Amir Dan Rubin

President and CEO, One Medical

Isaac (Zac) Kohane

Isaac (Zac) Kohane

Professor of Pediatrics, Harvard University

Sachin Kheterpal

Sachin Kheterpal

Associate Professor, Anesthesiology, UM

Event Highlights

When
June 6, 2018 8:00am to June 7, 2018 5:00pm
Where
Ross School of Business
701 Tappan Ave
Ann Arbor, MI 48109
Cost
$774 by May 2nd, 2018

Registration: PMWC Conferences

Michigan June 6-7, 2018

First PMWC In Midwest
2 Track Speaker Lineup
Access to the exhibition
Breakfast & lunch refreshments
Award Reception

Having Trouble Registering? We accept all major credit cards. Select 'PayPal Check out' and press 'Pay with Debit or Credit Card'.
Click here or call (650)-961-8877 to contact the PMWC Team for Help or to ask about the academic rate.